Abstract Library

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,